{"url_path":"/sec/ints/8-k/2026-08-11/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1567264/0001567264-26-000061-index.html","accession_number":"0001567264-26-000061","cik":"0001567264","ticker":"INTS","issuer_name":"INTENSITY THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1567264/0001567264-26-000061-index.html","primary_entity_key":"0001567264","primary_entity_name":"INTENSITY THERAPEUTICS, INC."},"word_count":234,"has_tables":true,"body_markdown":"Item 9.01. Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit No.Description\n\n99.1\n[Press Release issued](ints20260811ex99120260630p.htm)[August 11](ints20260811ex99120260630p.htm)[, 2026.](ints20260811ex99120260630p.htm)\n\n104Cover Page Interactive Data File (formatted in Inline XBRL).\n\nCAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS\n\nComments in this Current Report on Form 8-K and in the exhibit attached hereto contain certain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act, which are based on management’s good faith expectations and beliefs concerning future developments. Actual results may differ materially from these expectations as a result of many factors. These factors include, but are not limited to, the risks and uncertainties described in the “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements” sections of the Company’s Annual Report on Form 10-K, filed on March 27, 2026, the Company's Quarterly Report on Form 10-Q, filed on May 7, 2026, and the Company's Quarterly Report on Form 10-Q, filed on August 11, 2026. The Company does not undertake any obligation to update such forward-looking statements. All market and industry data are based on Company estimates.\n\n1\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDated: August 11, 2026\n\nIntensity Therapeutics, Inc.\n\nBy:/s/ Lewis H. Bender\n\nName: Lewis H. Bender\n\nTitle:Chief Executive Officer\n\n[Signature Page to the Form 8-K]\n\n2"}